Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1991 Apr 6;302(6780):824–828. doi: 10.1136/bmj.302.6780.824

Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom.

C R Buchanan 1, M A Preece 1, R D Milner 1
PMCID: PMC1669149  PMID: 2025705

Abstract

OBJECTIVE--To determine the cause of death and incidence of neoplasia in patients treated with human pituitary growth hormone. DESIGN--A long term cohort study established to receive details of death certification and tumour registrations through the Office of Population Censuses and Surveys and NHS central register. PATIENTS--All patients (1246 male, 662 female) treated for short stature with pituitary growth hormone under the Medical Research Council working party and health services human growth hormone committee. MAIN OUTCOME MEASURES--Death or development of neoplasia. RESULTS--110 patients died (68 male, 42 female; aged 0.9-57 years) from 1972 to 1990. Fifty three death were from neoplasia responsible for growth hormone deficiency (27 craniopharyngioma, 24 other intracranial tumour, two leukaemia); two from histiocytosis X; and 13 from pituitary insufficiency. Six patients died of Creutzfeldt-Jakob disease, six of other neurological disorders, and eight of acute infection. Other deaths were apparently unrelated to growth hormone deficiency or its treatment. Seventeen tumours (in 16 patients) were identified during or after growth hormone treatment. Four were in patients with previous intracranial neoplasia and two were after cranial irradiation. Thirteen were intracranial, the others being Hodgkin's lymphoma, osteosarcoma, carcinoma of colon, and basal cell carcinoma. CONCLUSIONS--Recurrence or progression of intracranial tumours and potentially avoidable metabolic consequences of hypopituitarism were the main causes of death. Growth hormone treatment probably did not contribute to new tumour development. Creutzfeldt-Jakob disease after pituitary growth hormone treatment continues to occur in the United Kingdom. This cohort must remain under long term review.

Full text

PDF
824

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arslanian S. A., Becker D. J., Lee P. A., Drash A. L., Foley T. P., Jr Growth hormone therapy and tumor recurrence. Findings in children with brain neoplasms and hypopituitarism. Am J Dis Child. 1985 Apr;139(4):347–350. doi: 10.1001/archpedi.1985.02140060029020. [DOI] [PubMed] [Google Scholar]
  2. Brown P., Gajdusek D. C., Gibbs C. J., Jr, Asher D. M. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med. 1985 Sep 19;313(12):728–731. doi: 10.1056/NEJM198509193131205. [DOI] [PubMed] [Google Scholar]
  3. Brown P. The decline and fall of Creutzfeldt-Jakob disease associated with human growth hormone therapy. Neurology. 1988 Jul;38(7):1135–1137. doi: 10.1212/wnl.38.7.1135. [DOI] [PubMed] [Google Scholar]
  4. Buchanan C. R., Law C. M., Milner R. D. Growth hormone in short, slowly growing children and those with Turner's syndrome. Arch Dis Child. 1987 Sep;62(9):912–916. doi: 10.1136/adc.62.9.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clayton P. E., Price D. A., Shalet S. M., Gattemaneni H. R. Craniopharyngioma recurrence and growth hormone therapy. Lancet. 1988 Mar 19;1(8586):642–642. doi: 10.1016/s0140-6736(88)91434-1. [DOI] [PubMed] [Google Scholar]
  6. Clayton P. E., Shalet S. M., Gattamaneni H. R., Price D. A. Does growth hormone cause relapse of brain tumours? Lancet. 1987 Mar 28;1(8535):711–713. doi: 10.1016/s0140-6736(87)90355-2. [DOI] [PubMed] [Google Scholar]
  7. Cochius J. I., Burns R. J., Blumbergs P. C., Mack K., Alderman C. P. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. Aust N Z J Med. 1990 Aug;20(4):592–593. doi: 10.1111/j.1445-5994.1990.tb01322.x. [DOI] [PubMed] [Google Scholar]
  8. Farwell J., Flannery J. T. Second primaries in children with central nervous system tumors. J Neurooncol. 1984;2(4):371–375. doi: 10.1007/BF00178120. [DOI] [PubMed] [Google Scholar]
  9. Goujard J., Entat M., Maillard F., Mugnier E., Rappaport R., Job J. C. Human pituitary growth hormone (hGH) and Creutzfeldt-Jakob disease: results of an epidemiological survey in France, 1986. Int J Epidemiol. 1988 Jun;17(2):423–427. doi: 10.1093/ije/17.2.423. [DOI] [PubMed] [Google Scholar]
  10. Kingston J. E., Hawkins M. M., Draper G. J., Marsden H. B., Kinnier Wilson L. M. Patterns of multiple primary tumours in patients treated for cancer during childhood. Br J Cancer. 1987 Sep;56(3):331–338. doi: 10.1038/bjc.1987.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Leukaemia in patients treated with growth hormone. Lancet. 1988 May 21;1(8595):1159–1160. [PubMed] [Google Scholar]
  12. Leukaemia in patients treated with growth hormone. Lancet. 1988 May 21;1(8595):1159–1160. [PubMed] [Google Scholar]
  13. Leukaemia in patients treated with growth hormone. Lancet. 1988 May 21;1(8595):1159–1160. [PubMed] [Google Scholar]
  14. Milner R. D., Barnes N. D., Buckler J. M., Carson D. J., Hadden D. R., Hughes I. A., Johnston D. I., Parkin J. M., Price D. A., Rayner P. H. United Kingdom multicentre clinical trial of somatrem. Arch Dis Child. 1987 Aug;62(8):776–779. doi: 10.1136/adc.62.8.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Milner R. D., Russell-Fraser T., Brook C. G., Cotes P. M., Farquhar J. W., Parkin J. M., Preece M. A., Snodgrass G. J., Mason A. S., Tanner J. M. Experience with human growth hormone in Great Britain: the report of the MRC Working Party. Clin Endocrinol (Oxf) 1979 Jul;11(1):15–38. doi: 10.1111/j.1365-2265.1979.tb03043.x. [DOI] [PubMed] [Google Scholar]
  16. New M. I., Brown P., Temeck J. W., Owens C., Hedley-Whyte E. T., Richardson E. P. Preclinical Creutzfeldt-Jakob disease discovered at autopsy in a human growth hormone recipient. Neurology. 1988 Jul;38(7):1133–1134. doi: 10.1212/wnl.38.7.1133. [DOI] [PubMed] [Google Scholar]
  17. Powell-Jackson J., Weller R. O., Kennedy P., Preece M. A., Whitcombe E. M., Newsom-Davis J. Creutzfeldt-Jakob disease after administration of human growth hormone. Lancet. 1985 Aug 3;2(8449):244–246. doi: 10.1016/s0140-6736(85)90292-2. [DOI] [PubMed] [Google Scholar]
  18. Preece M. A. Creutzfeldt-Jakob disease: implications for growth hormone deficient children. Neuropathol Appl Neurobiol. 1986 Sep-Oct;12(5):509–515. doi: 10.1111/j.1365-2990.1986.tb00061.x. [DOI] [PubMed] [Google Scholar]
  19. RABEN M. S. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958 Aug;18(8):901–903. doi: 10.1210/jcem-18-8-901. [DOI] [PubMed] [Google Scholar]
  20. Sherwood M. C., Stanhope R., Preece M. A., Grant D. B. Diabetes insipidus and occult intracranial tumours. Arch Dis Child. 1986 Dec;61(12):1222–1224. doi: 10.1136/adc.61.12.1222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Stahnke N., Zeisel H. J. Growth hormone therapy and leukaemia. Eur J Pediatr. 1989 Jun;148(7):591–596. doi: 10.1007/BF00441506. [DOI] [PubMed] [Google Scholar]
  22. Standen G. R., Hughes I. A., Geddes A. D., Jones B. M., Wardrop C. A. Myelodysplastic syndrome with trisomy 8 in an adolescent with Fanconi anaemia and selective IgA deficiency. Am J Hematol. 1989 Aug;31(4):280–283. doi: 10.1002/ajh.2830310413. [DOI] [PubMed] [Google Scholar]
  23. Stanhope R., Preece M. A., Grant D. B., Brook C. G. Is diabetes insipidus during childhood ever idiopathic? Br J Hosp Med. 1989 May;41(5):490–491. [PubMed] [Google Scholar]
  24. Tanner J. M., Whitehouse R. H., Hughes P. C., Vince F. P. Effect of human growth hormone treatment for 1 to 7 years on growth of 100 children, with growth hormone deficiency, low birthweight, inherited smallness, Turner's syndrome, and other complaints. Arch Dis Child. 1971 Dec;46(250):745–782. doi: 10.1136/adc.46.250.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Weller R. O., Steart P. V., Powell-Jackson J. D. Pathology of Creutzfeldt-Jakob disease associated with pituitary-derived human growth hormone administration. Neuropathol Appl Neurobiol. 1986 Mar-Apr;12(2):117–129. doi: 10.1111/j.1365-2990.1986.tb00045.x. [DOI] [PubMed] [Google Scholar]
  26. Whitehead H. M., Hadden D. R., Carson D. J. The Northern Ireland experience of growth hormone therapy for short stature. Ulster Med J. 1989 Oct;58(2):153–160. [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES